Catalog No.
PHD17901
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human MGMT (Met1-Asn207).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
MGMT,6-O-methylguanine-DNA methyltransferase,Methylated-DNA--protein-cysteine methyltransferase,O-6-methylguanine-DNA-alkyltransferase
Purification
Purified by antigen affinity column.
Accession
P16455
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Loss of O6-Methylguanine-DNA Methyltransferase Protein Expression by Immunohistochemistry Is Associated With Response to Capecitabine and Temozolomide in Neuroendocrine Neoplasms., PMID:39825572
Congress of Neurological Surgeons systematic review and evidence based guideline on neuropathology for WHO grade II diffuse glioma: update., PMID:39747718
A Novel IgG-IgM Autoantibody Panel Enhances Detection of Early-stage Lung Adenocarcinoma from Benign Nodules., PMID:39661479
Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas., PMID:39572979
A case series of osseous metastases in patients with glioblastoma., PMID:38968484
Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse., PMID:38551747
Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide., PMID:38263486
Classification of gliomas based on genome-wide DNA methylation profiles and immunohistochemical analysis: a short study., PMID:39963031
Unveiling the role of MGMT and DAPK hypermethylation in response to anti-EGFR agents: Molecular insights for advancing HNSCC treatment., PMID:38095042
The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial., PMID:37787906
Unraveling the signaling mechanism behind astrocytoma and possible therapeutics strategies: A comprehensive review., PMID:37675821
Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial., PMID:37494539
Re-irradiation for recurrent high-grade glioma: an analysis of prognostic factors for survival and predictors of radiation necrosis., PMID:37256526
Late-line treatment with bevacizumab alone or in combination with chemotherapy in recurrent high-grade gliomas., PMID:36781461
Dose-dependent efficacy of bevacizumab in recurrent glioblastoma., PMID:36749445
Efficacy and Safety of Bevacizumab for Treating Glioblastoma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials., PMID:36705341
ProNGF Expression and Targeting in Glioblastoma Multiforme., PMID:36675126
Targeted therapies in patients with newly diagnosed glioblastoma-A systematic meta-analysis of randomized clinical trials., PMID:36647335
Clinical Benefit of Bevacizumab and Irinotecan (BEV+IRI) in Patients With Relapsed/Refractory Glioblastoma (r/rGBM) and its Potential Predictors., PMID:36456153
Experimental study of selective MGMT peptides mimicking TMZ drug resistance in glioma., PMID:36407484
Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101., PMID:36379185
The road we travel., PMID:36219132
Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study., PMID:36181764
Prospects for the use of blood elemental status to assess the molecular genetic profile of gliomas., PMID:36099457
ELEVATE - evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial., PMID:36050653
CD93 is Associated with Glioma-related Malignant Processes and Immunosuppressive Cell Infiltration as an Inspiring Biomarker of Survivance., PMID:36006582
Immune-checkpoint inhibitors for glioblastoma: what have we learned?, PMID:35976319
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial., PMID:35849035
Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of neuropathology in the management of progressive glioblastoma in adults., PMID:35648306
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter., PMID:35511454
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial., PMID:35419607
Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma., PMID:35395080
Novel electrochemical immunosensor for O6-methylguanine-DNA methyltransferase gene methylation based on graphene oxide-magnetic nanoparticles-β-cyclodextrin nanocomposite., PMID:35378463
Towards maximum acceleration of monoclonal antibody development: Leveraging transposase-mediated cell line generation to enable GMP manufacturing within 3 months using a stable pool., PMID:35341894
Profiling demethylase activity using epigenetically inactivated DNAzyme., PMID:35316758
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial., PMID:35258987
The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients., PMID:34875075
Infratentorial Stereotactic Biopsy of Brainstem and Cerebellar Lesions., PMID:34827431
A Novel Blood-Brain Barrier-Permeable Chemotherapeutic Agent for the Treatment of Glioblastoma., PMID:34646647
Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: a phase I/II clinical trial., PMID:34601657
Covalent 18F-Radiotracers for SNAPTag: A New Toolbox for Reporter Gene Imaging., PMID:34577597
Immunohistochemical expression of MGMT in gliomas and its role in ascertaining patient survival., PMID:34430853
Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)., PMID:34204877
Ketogenic Metabolic Therapy, Without Chemo or Radiation, for the Long-Term Management of IDH1-Mutant Glioblastoma: An 80-Month Follow-Up Case Report., PMID:34136522
Advanced Molecular Characterization Using Digital Spatial Profiling Technology on Immunooncology Targets in Methylated Compared with Unmethylated IDH-Wildtype Glioblastoma., PMID:33995529
Integrated analysis of programmed cell death ligand 1 expression reveals increased levels in high-grade glioma., PMID:33963441
Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma., PMID:33838014
Initial Results of a Phase 2 Trial of 18F-DOPA PET-Guided Dose-Escalated Radiation Therapy for Glioblastoma., PMID:33771703
Dynamic contrast-enhanced MRI may be helpful to predict response and prognosis after bevacizumab treatment in patients with recurrent high-grade glioma: comparison with diffusion tensor and dynamic susceptibility contrast imaging., PMID:33755766
LAG-3 expression in the inflammatory microenvironment of glioma., PMID:33651248
For research use only. Not for human or drug use.
